Annual EBITDA
-$81.90 M
+$15.87 M+16.23%
31 December 2023
Summary:
UroGen Pharma annual earnings before interest, taxes, depreciation & amortization is currently -$81.90 million, with the most recent change of +$15.87 million (+16.23%) on 31 December 2023. During the last 3 years, it has risen by +$42.79 million (+34.32%). URGN annual EBITDA is now -8201.29% below its all-time high of $1.01 million, reached on 31 December 2016.URGN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$20.59 M
+$9.05 M+30.52%
30 September 2024
Summary:
UroGen Pharma quarterly earnings before interest, taxes, depreciation & amortization is currently -$20.59 million, with the most recent change of +$9.05 million (+30.52%) on 30 September 2024. Over the past year, it has dropped by -$2.94 million (-16.63%). URGN quarterly EBITDA is now -247.30% below its all-time high of $13.98 million, reached on 31 December 2016.URGN Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$97.82 M
-$2.94 M-3.10%
30 September 2024
Summary:
UroGen Pharma TTM earnings before interest, taxes, depreciation & amortization is currently -$97.82 million, with the most recent change of -$2.94 million (-3.10%) on 30 September 2024. Over the past year, it has dropped by -$9.56 million (-10.84%). URGN TTM EBITDA is now -2239.59% below its all-time high of $4.57 million, reached on 31 December 2016.URGN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
URGN EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +16.2% | -16.6% | -10.8% |
| 3 y3 years | +34.3% | +30.8% | +9.1% |
| 5 y5 years | -6.7% | +11.0% | -5.6% |
URGN EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +34.3% | -16.6% | +30.8% | -19.4% | +10.6% |
| 5 y | 5 years | -6.7% | +34.3% | -16.6% | +47.8% | -19.4% | +28.9% |
| alltime | all time | -8201.3% | +34.3% | -247.3% | +47.8% | -2239.6% | +28.9% |
UroGen Pharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$20.59 M(-30.5%) | -$97.82 M(+3.1%) |
| June 2024 | - | -$29.64 M(+0.7%) | -$94.89 M(+11.5%) |
| Mar 2024 | - | -$29.43 M(+62.2%) | -$85.13 M(+3.9%) |
| Dec 2023 | -$81.90 M(-16.2%) | -$18.15 M(+2.8%) | -$81.90 M(-7.2%) |
| Sept 2023 | - | -$17.66 M(-11.2%) | -$88.26 M(-4.7%) |
| June 2023 | - | -$19.89 M(-24.1%) | -$92.59 M(-4.2%) |
| Mar 2023 | - | -$26.20 M(+6.9%) | -$96.65 M(-1.2%) |
| Dec 2022 | -$97.77 M(-9.1%) | -$24.51 M(+11.4%) | -$97.77 M(-2.4%) |
| Sept 2022 | - | -$21.99 M(-8.1%) | -$100.13 M(-7.2%) |
| June 2022 | - | -$23.94 M(-12.4%) | -$107.90 M(-1.4%) |
| Mar 2022 | - | -$27.33 M(+1.7%) | -$109.42 M(+1.5%) |
| Dec 2021 | -$107.60 M(-13.7%) | -$26.86 M(-9.7%) | -$107.78 M(+0.2%) |
| Sept 2021 | - | -$29.76 M(+16.8%) | -$107.55 M(+1.1%) |
| June 2021 | - | -$25.47 M(-0.8%) | -$106.42 M(-5.2%) |
| Mar 2021 | - | -$25.69 M(-3.6%) | -$112.28 M(-10.0%) |
| Dec 2020 | -$124.69 M | -$26.64 M(-6.9%) | -$124.69 M(-9.3%) |
| Sept 2020 | - | -$28.63 M(-8.6%) | -$137.50 M(+4.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2020 | - | -$31.32 M(-17.8%) | -$132.01 M(+6.3%) |
| Mar 2020 | - | -$38.10 M(-3.4%) | -$124.13 M(+14.8%) |
| Dec 2019 | -$108.15 M(+40.9%) | -$39.44 M(+70.4%) | -$108.15 M(+16.7%) |
| Sept 2019 | - | -$23.14 M(-1.3%) | -$92.66 M(+2.3%) |
| June 2019 | - | -$23.45 M(+6.0%) | -$90.55 M(+5.9%) |
| Mar 2019 | - | -$22.13 M(-7.6%) | -$85.49 M(+11.4%) |
| Dec 2018 | -$76.76 M(+288.8%) | -$23.95 M(+13.9%) | -$76.76 M(+22.0%) |
| Sept 2018 | - | -$21.03 M(+14.4%) | -$62.91 M(+49.2%) |
| June 2018 | - | -$18.38 M(+37.2%) | -$42.17 M(+42.2%) |
| Mar 2018 | - | -$13.40 M(+32.7%) | -$29.65 M(+50.2%) |
| Dec 2017 | -$19.74 M(-2052.8%) | -$10.10 M(+3431.5%) | -$19.74 M(-555.0%) |
| Sept 2017 | - | -$286.00 K(-95.1%) | $4.34 M(-403.9%) |
| June 2017 | - | -$5.86 M(+67.9%) | -$1.43 M(-232.3%) |
| Mar 2017 | - | -$3.49 M(-125.0%) | $1.08 M(-76.4%) |
| Dec 2016 | $1.01 M(-108.2%) | $13.98 M(-331.0%) | $4.57 M(-148.6%) |
| Sept 2016 | - | -$6.05 M(+80.3%) | -$9.41 M(+180.3%) |
| June 2016 | - | -$3.36 M | -$3.36 M |
| Dec 2015 | -$12.30 M | - | - |
FAQ
- What is UroGen Pharma annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for UroGen Pharma?
- What is UroGen Pharma annual EBITDA year-on-year change?
- What is UroGen Pharma quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for UroGen Pharma?
- What is UroGen Pharma quarterly EBITDA year-on-year change?
- What is UroGen Pharma TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for UroGen Pharma?
- What is UroGen Pharma TTM EBITDA year-on-year change?
What is UroGen Pharma annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of URGN is -$81.90 M
What is the all time high annual EBITDA for UroGen Pharma?
UroGen Pharma all-time high annual earnings before interest, taxes, depreciation & amortization is $1.01 M
What is UroGen Pharma annual EBITDA year-on-year change?
Over the past year, URGN annual earnings before interest, taxes, depreciation & amortization has changed by +$15.87 M (+16.23%)
What is UroGen Pharma quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of URGN is -$20.59 M
What is the all time high quarterly EBITDA for UroGen Pharma?
UroGen Pharma all-time high quarterly earnings before interest, taxes, depreciation & amortization is $13.98 M
What is UroGen Pharma quarterly EBITDA year-on-year change?
Over the past year, URGN quarterly earnings before interest, taxes, depreciation & amortization has changed by -$2.94 M (-16.63%)
What is UroGen Pharma TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of URGN is -$97.82 M
What is the all time high TTM EBITDA for UroGen Pharma?
UroGen Pharma all-time high TTM earnings before interest, taxes, depreciation & amortization is $4.57 M
What is UroGen Pharma TTM EBITDA year-on-year change?
Over the past year, URGN TTM earnings before interest, taxes, depreciation & amortization has changed by -$9.56 M (-10.84%)